Targeting Viral RNA-Dependent RNA Polymerases as an Antiviral Therapy
-
Published:2021-12
Issue:40
Volume:28
Page:8384-8391
-
ISSN:0929-8673
-
Container-title:Current Medicinal Chemistry
-
language:en
-
Short-container-title:CMC
Author:
Miranda Daniel1ORCID,
Sanchez David Jesse1ORCID
Affiliation:
1. Pharmaceutical Sciences Department, College of Pharmacy, Western University of Health Sciences, Pomona, California,United States
Abstract
Progressive globalization of our society brings not only worldwide integration,
it also increases and promotes our exposure to new viral pathogens with evident impacts
on our global health. Especially with the emergence of SARS-CoV-2, our biomedical research
infrastructure has never been more compelled to rapidly develop antiviral regimens
that demonstrate improved efficacy against these pathogens. Here, we showcase 3 poignant
antivirals against the lucrative target, RNA-dependent RNA polymerase (RdRP) of
RNA viruses – a timely and relevant topic given the present efforts against COVID-19.
While effective drug designs against RdRP are important, their benefit and potential as a
standard of care truly relies on them standing out in well-designed clinical trials.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献